サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1696284

リンパ浮腫の世界市場（2025年～2033年）

Global Lymphedema Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
リンパ浮腫の世界市場（2025年～2033年）
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のリンパ浮腫の市場規模は、2024年に9億8,985万米ドルに達し、2033年までに20億2,990万米ドルに達すると予測され、2025年～2033年の予測期間にCAGRで8.8%の成長が見込まれます。

リンパ浮腫とは、通常身体のリンパ系を通じて排出されるタンパク質を多く含む体液の蓄積によって引き起こされる組織の腫脹を指します。リンパ浮腫は腕や脚に生じることがもっとも多いですが、胸壁、腹部、頸部、生殖器にも生じることがあります。リンパ浮腫は、リンパ節を切除したり損傷したりするがん治療によって引き起こされることがあります。リンパ液の排出を阻害するあらゆる原因がリンパ浮腫を引き起こす可能性があります。

市場力学

促進要因と抑制要因

リンパ浮腫治療技術の進歩

世界のリンパ浮腫市場の需要は、複数の要因によって促進されています。主な要因の1つは、医療システムにおける技術の進歩です。リンパ浮腫は慢性的な症状であり、通常はリンパ液の排出不足によって引き起こされます。主要企業による革新的な技術の進歩は、市場成長を促進します。これらの効果的な進歩は、研究の発見を新たな治療に転換し、何百万人ものリンパ浮腫患者のケアを改善するのに役立っています。

例えば2022年10月、ImpediMed Limitedは、乳がん患者に対するリンパ浮腫の影響を軽減することに特化した、主要ながんセンターにおける同社のSOZOデジタルヘルスプラットフォームの使用の拡大を発表しました。さらに、リンパ浮腫の治療において先進の研究開発を導入し、新しい治療法や医薬品を発売する主要企業は、この市場の成長を促進するとみられます。

さらに、リンパ浮腫の有病率の増加、臨床試験の増加、認知度の向上、新薬や治療法の開発における進歩は、市場を牽引すると予測される要因です。

認識不足

世界のリンパ浮腫市場の成長を妨げている重要な課題の1つは、患者と医療提供者の双方における認識不足です。リンパ浮腫は世界中で数百万人に影響を及ぼしているにもかかわらず、診断や治療が不十分なままであり、介入の遅れや健康転帰の悪化につながっています。

多くの患者は、腫れ、重苦しさ、皮膚の変化などの初期症状に気づかず、診断の遅れにつながっています。リンパ浮腫を、継続的な管理が必要な生涯にわたる慢性疾患ではなく、一時的な症状であると誤解している人もいます。したがって、上記の要因が世界のリンパ浮腫市場の潜在的成長を制限している可能性があります。

当レポートでは、世界のリンパ浮腫市場について調査し、市場力学、地域とセグメントの分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブインサイトと重要事項

  • 市場のハイライトと戦略的ポイント
  • 主要動向と将来の予測
  • 抜粋：タイプ別
  • 抜粋：治療タイプ別
  • 抜粋：エンドユーザー別
  • 抜粋：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • リンパ浮腫治療技術の進歩
      • リンパ浮腫の有病率の増加
    • 抑制要因
      • 認識不足
      • 治療手技の高いコスト
    • 機会
      • 個別化治療の増加
    • 影響の分析

第4章 戦略的考察と産業の見通し

  • マーケットリーダーとパイオニア
    • 新興パイオニアと著名企業
    • 確立されたリーダーともっとも売れているブランド
    • マーケットリーダーと確立された製品
  • CXOの視点
  • 最新の発展とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大に対し推奨される戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 リンパ浮腫市場：タイプ別

  • 原発性リンパ浮腫
  • 続発性リンパ浮腫

第6章 リンパ浮腫市場：治療タイプ別

  • 薬剤タイプ
    • ケトプロフェン
    • フルクロキサシリン
    • アモキシシリン
  • うっ血緩和リンパ浮腫療法（DLT）
    • マニュアルリンパドレナージ（MLD）
    • 圧縮デバイス
      • 圧縮ポンプ
      • 圧縮ラップ
      • 圧縮ストッキング
      • 圧迫帯
  • 手術
    • 減量手術
    • 血管柄付きリンパ節移植（VLNT）
    • リンパ管静脈吻合術（LVA）
    • SAPL（Suction-Assisted Protein Lipectomy）
  • レーザー療法
  • その他

第7章 リンパ浮腫市場：エンドユーザー別

  • 病院
  • 専門クリニック
  • 外来手術センター
  • その他

第8章 リンパ浮腫市場：地域別、市場の分析と成長機会

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • ラテンアメリカ
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他のラテンアメリカ
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合情勢の概要と主要市場企業
  • 市場シェア分析とポジショニングマトリクス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Tactile Medical
  • Bio Compression Systems, Inc.
  • BSN-JOBST, Inc.
  • Sigvaris group
  • Lohmann & Rauscher (L&R)
  • AIROS Medical, Inc.
  • Arjo
  • Venturelab Ltd.
  • LymphaCare
  • Absolute Medical, Inc.

第11章 前提条件と調査手法

第12章 付録

目次
Product Code: PH9420

The global lymphedema market reached US$ 989.85 million in 2024 and is expected to reach US$ 2,029.90 million by 2033, growing at a CAGR of 8.8 % during the forecast period of 2025-2033.

Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid that's usually drained through the body's lymphatic system. It most commonly affects the arms or legs, but can also occur in the chest wall, abdomen, neck, and genitals. Lymphedema can be caused by cancer treatments that remove or damage the lymph nodes. Any cause that blocks the drainage of lymph fluid can lead to lymphedema.

Market Dynamics: Drivers & Restraints

Increasing Technological Advancements for Lymphedema Treatment

The demand for the global lymphedema market is driven by multiple factors. One of the key factors is the technological advancements in the healthcare system. Lymphedema is a chronic condition that is usually caused by insufficient lymphatic drainage. The innovative technological advancements by key companies help to drive market growth. These effective advancements help to transform research discoveries into new treatments and improve care for millions of people with lymphedema.

For instance, in October 2022, ImpediMed Limited announced the expansion of the use of its SOZO Digital Health Platform at leading cancer centers dedicated to reducing the impact of lymphedema on breast cancer patients. Moreover, key players introducing advanced research & developments in treating lymphedema and launching new therapies & drugs would drive this market growth.

Further, the increasing prevalence of lymphedema, increasing clinical trials, increasing awareness, and advancements in the development of novel drugs and therapies are the factors expected to drive the market.

Lack of Awareness

One of the significant challenges hindering the growth of the global lymphedema market is the lack of awareness among both patients and healthcare providers. Despite lymphedema affecting millions worldwide, it remains underdiagnosed and undertreated, leading to delayed intervention and poorer health outcomes.

Many patients are unaware of early symptoms, such as swelling, heaviness, or skin changes, leading to delayed diagnosis. Some people mistakenly believe lymphedema is a temporary condition rather than a lifelong chronic disease that requires continuous management. Thus, the above factors could be limiting the global lymphedema market's potential growth.

Segment Analysis

The global lymphedema market is segmented based on type, treatment type, end-user, and region.

Treatment Type:

The decongestive lymphedema therapy (DLT) segment in treatment type is expected to dominate the global lymphedema market with the highest market share

Decongestive lymphatic therapy (CDT) is used to provide permanent control of the volumetric and metaplastic tissue changes associated with lymphedema. The therapy includes manual lymphatic drainage and compression among others. Intermittent pneumatic compression pumps are used to treat lymphedema symptoms.

Decongestive lymphatic therapy (DLT) is the cornerstone of lymphedema management and a key segment of the global lymphedema treatment market. This multimodal approach combines compression therapy, manual lymphatic drainage, exercise, and skin care to reduce swelling and improve quality of life for patients with chronic fluid retention.

The companies are receiving approvals for advanced devices for patients with lymphedema. These advanced devices could help in maintaining the disease condition rather than making it worse. For instance, in March 2024, Extremit-Ease Compression Garment, by AMERX Health Care, received approval from PDAC for code A6583, one of the 78 new codes issued under the new Lymphedema Treatment Act (LTA). These factors have solidified the segment's position in the global lymphedema market.

Geographical Analysis

North America is expected to hold a significant position in the global lymphedema market with the highest market share

The region is expected to hold the dominant position during the forecast period, owing to the rising prevalence of lymphedema and rising breast cancer in the U.S. and Canada, driving the market growth. For instance, according to the Lymphatic Education & Research Network, it is stated that around 10 million Americans suffer from Lymphedema.

Additionally, the key strategies among the market players, such as collaboration partnerships and product launches, are also expected to propel the market growth. For instance, in June 2023, PAUL HARTMANN AG announced its partnership with Sigvaris for the innovative compression wraps and liners range that are used as compression therapy for the treatment of lymphedema. Thus, the above factors are consolidating the region's position as a dominant force in the global lymphedema market.

Competitive Landscape

The major global players in the lymphedema market include Tactile Medical, Bio Compression Systems, Inc., BSN-JOBST, Inc., Sigvaris group, Lohmann & Rauscher (L&R), AIROS Medical, Inc., Arjo, Venturelab Ltd., LymphaCare, and Absolute Medical, Inc., among others.

Key Developments

  • In September 2023, AIROS Medical, Inc. announced the availability of the AIROS 6P sequential compression device and pants-like compression garments that treat abdominal, pelvic, and leg swelling. The company launched the AIROS 8P sequential compression device and similar garments earlier this year.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global lymphedema market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Treatment Type
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Increasing Technological Advancements for Lymphedema Treatment
      • 3.1.1.2. Increasing Prevalence of Lymphedema
    • 3.1.2. Restraints
      • 3.1.2.1. Lack of Awareness
      • 3.1.2.2. High Cost of the Treatment Procedure
    • 3.1.3. Opportunity
      • 3.1.3.1. Increasing Personalized Treatments
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with the largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Lymphedema Market, By Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index By Type
  • 5.2. Primary Lymphedema*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Secondary Lymphedema

6. Lymphedema Market, By Treatment Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 6.1.2. Market Attractiveness Index By Treatment Type
  • 6.2. Drug Type*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Ketoprofen
    • 6.2.4. Flucloxacillin
    • 6.2.5. Amoxicillin
  • 6.3. Decongestive Lymphedema Therapy (DLT)
    • 6.3.1. Manual Lymphatic Drainage (MLD)
    • 6.3.2. Compression Devices
      • 6.3.2.1. Compression Pumps
      • 6.3.2.2. Compression Wraps
      • 6.3.2.3. Compression Stocking
      • 6.3.2.4. Compression Garments
  • 6.4. Surgery
    • 6.4.1. Debulking Surgery
    • 6.4.2. Vascularized Lymph Node Transfer (VLNT)
    • 6.4.3. Lymphaticovenous Anastomoses (LVA)
    • 6.4.4. Suction-Assisted Protein Lipectomy (SAPL)
  • 6.5. Laser Therapy
  • 6.6. Others

7. Lymphedema Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Ambulatory Surgical Centers
  • 7.5. Others

8. Lymphedema Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Latin America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Mexico
      • 8.4.6.2. Brazil
      • 8.4.6.3. Argentina
      • 8.4.6.4. Rest of Latin America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Tactile Medical*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
    • 10.1.3. Financial Overview
      • 10.1.3.1. Company Revenue
      • 10.1.3.2. Geographical Revenue Shares
      • 10.1.3.3. Revenue Forecasts
    • 10.1.4. Key Developments
      • 10.1.4.1. Mergers & Acquisitions
      • 10.1.4.2. Key Product Development Activities
      • 10.1.4.3. Regulatory Approvals, etc.
    • 10.1.5. SWOT Analysis
  • 10.2. Bio Compression Systems, Inc.
  • 10.3. BSN-JOBST, Inc.
  • 10.4. Sigvaris group
  • 10.5. Lohmann & Rauscher (L&R)
  • 10.6. AIROS Medical, Inc.
  • 10.7. Arjo
  • 10.8. Venturelab Ltd.
  • 10.9. LymphaCare
  • 10.10. Absolute Medical, Inc.

LIST NOT EXHAUSTIVE

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us